AI-driven pipeline discovers ombuin as a novel M1 macrophage polarization inhibitor for sepsis treatment.

Saved in:
Bibliographic Details
Title: AI-driven pipeline discovers ombuin as a novel M1 macrophage polarization inhibitor for sepsis treatment.
Authors: Gong SC; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.; Taizhou Institute of Zhejiang University, Zhejiang University, Taizhou, 318000, China.; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China., Jiang L; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China., Li QX; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.; ZJU-Xinchang Joint Innovation Center (TianMu Laboratory)), Xinchang, 312500, China., Yang C; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China., Yu L; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.; Taizhou Institute of Zhejiang University, Zhejiang University, Taizhou, 318000, China., Lv SY; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China., Yang G; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China., Yang ZX; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.; Taizhou Institute of Zhejiang University, Zhejiang University, Taizhou, 318000, China., Huang H; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China., Hu YM; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China., Chen XY; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China., Zhang HY; Institute of Intelligent Transportation Systems, College of Civil Engineering and Architecture, Zhejiang University, Hangzhou, 310007, China., Yang B; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.; School of Medicine, Hangzhou City University, Hangzhou, 310015, China., He QJ; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China.; ZJU-Xinchang Joint Innovation Center (TianMu Laboratory)), Xinchang, 312500, China.; The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.; Department of Pharmaceutical and Translational Toxicology, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, 310058, China., Weng QJ; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China. wengqinjie@zju.edu.cn.; Taizhou Institute of Zhejiang University, Zhejiang University, Taizhou, 318000, China. wengqinjie@zju.edu.cn.; The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China. wengqinjie@zju.edu.cn.; Institute of Fundamental and Transdisciplinary Research Zhejiang University, Zhejiang University, Hangzhou, 310058, China. wengqinjie@zju.edu.cn., Wang JC; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310007, China. wangjincheng@zju.edu.cn.; Taizhou Institute of Zhejiang University, Zhejiang University, Taizhou, 318000, China. wangjincheng@zju.edu.cn.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Jul; Vol. 47 (7), pp. 1900-1916. Date of Electronic Publication: 2026 Feb 24.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1745-7254
DOI:10.1038/s41401-026-01752-6